KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EBT (2016 - 2025)

NovoCure (NVCR) has disclosed EBT for 12 consecutive years, with -$41.0 million as the latest value for Q4 2025.

  • Quarterly EBT rose 25.82% to -$41.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$136.2 million through Dec 2025, down 3.88% year-over-year, with the annual reading at -$136.2 million for FY2025, 3.88% down from the prior year.
  • EBT hit -$41.0 million in Q4 2025 for NovoCure, down from -$30.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$2.5 million in Q1 2022 to a low of -$55.2 million in Q4 2024.
  • Historically, EBT has averaged -$29.7 million across 5 years, with a median of -$30.2 million in 2025.
  • Biggest five-year swings in EBT: tumbled 1931.01% in 2023 and later skyrocketed 57.83% in 2024.
  • Year by year, EBT stood at -$25.6 million in 2021, then decreased by 27.31% to -$32.6 million in 2022, then fell by 18.35% to -$38.5 million in 2023, then plummeted by 43.27% to -$55.2 million in 2024, then increased by 25.82% to -$41.0 million in 2025.
  • Business Quant data shows EBT for NVCR at -$41.0 million in Q4 2025, -$30.0 million in Q3 2025, and -$35.0 million in Q2 2025.